Bromhexine vs placebo
Lung function (FEV₁) · people with bronchiectasis
Bromhexine showed no clear difference in lung function FEV1 compared with placebo (low certainty).
1 finding from 1 review
- MD 1841 study · 88 participantsLow
Findings
What do systematic reviews say?
539 questions · 553 findings · 58 reviews · Airways
No studies found 37 · 6.7%GRADE not reported 8 · 1.4%Very low 27 · 4.9%Low 161 · 29.1%Moderate 219 · 39.6%High 101 · 18.3%
RhDNase vs placebo
Frequency and duration of exacerbations · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
RhDNase vs placebo
Hospitalisations for infective exacerbations · people with bronchiectasis
RhDNase showed no clear difference in hospitalisations for infective exacerbations compared with placebo (low certainty).
1 finding from 1 review
- OR 5.54 [0.25, 123.08]1 study · 40 participantsLow
Summary of findings ‐ Inhaled mannitol vs placebo
Annual Exacerbation Rates · people with bronchiectasis
Inhaled mannitol showed no clear difference in exacerbations Exacerbation rate per year. compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.92 [0.78, 1.08]1 study · 461 participantsModerate
Summary of findings ‐ Inhaled mannitol vs placebo
Hospitalisations Number of participants experiencing one of more hospitalisations. · people with bronchiectasis
Inhaled mannitol showed no clear difference in hospitalisations Number of participants experiencing one of more… compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.61 [0.34, 1.09]1 study · 461 participantsModerate
Summary of findings ‐ Inhaled mannitol vs placebo
Adverse events · people with bronchiectasis
Inhaled mannitol showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- OR 0.96 [0.61, 1.51]2 studies · 804 participantsModerate
Summary of findings ‐ Inhaled mannitol vs placebo
All‐cause mortality · people with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Summary of findings ‐ Inhaled mannitol vs placebo
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · people with bronchiectasis
Inhaled mannitol showed no clear difference in health‐related quality of life measured on the SGRQ Scale from 0 to… compared with placebo (moderate certainty).
1 finding from 1 review
- no estimate extracted3 studies · 840 participantsModerate
Summary of findings ‐ Inhaled mannitol vs placebo
Symptoms Bronchiectasis Symptoms Questionnaire · people with bronchiectasis
Inhaled mannitol showed no clear difference in symptoms Bronchiectasis Symptoms Questionnaire compared with placebo (moderate certainty).
1 finding from 1 review
- no estimate extracted1 study · 343 participantsModerate
Summary of findings ‐ Inhaled mannitol vs placebo
FEV1 (L) · people with bronchiectasis
Inhaled mannitol showed no clear difference in lung function FEV1 (L) compared with placebo (moderate certainty).
1 finding from 1 review
- MD 0.031 study · 343 participantsModerate
Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid)
Exacerbations · people with asthma
Subcutaneous omalizumab + steroid probably leads to lower number of participants with at least one exacerbation All asthmatic… compared with placebo + steroid (stable steroid) (moderate certainty).
1 finding from 1 review
- OR 0.55 [0.46, 0.65]10 studies · 3261 participantsModerate
Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid)
Exacerbations (number of people experiencing ≥ 1 exacerbations) · people with asthma
Subcutaneous omalizumab + steroid probably leads to lower number of participants with at least one exacerbation Moderate to… compared with placebo + steroid (stable steroid) (moderate certainty).
1 finding from 1 review
- OR 0.5 [0.42, 0.6]7 studies · 2889 participantsModerate
Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid)
Number of participants with at least one exacerbation Severe asthma (16 to 32 weeks) · people with asthma
Subcutaneous omalizumab + steroid showed no clear difference in number of participants with at least one exacerbation Severe asthma… compared with placebo + steroid (stable steroid) (low certainty).
1 finding from 1 review
- OR 1 [0.5, 1.99]2 studies · 277 participantsLow
Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid)
Mortality 16 to 60 weeks · people with asthma
Subcutaneous omalizumab + steroid showed no clear difference in mortality 16 to 60 weeks compared with placebo + steroid (stable steroid) (low certainty).
1 finding from 1 review
- OR 0.19 [0.02, 1.67]9 studies · 4245 participantsLow
Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid)
Hospitalisations 28 to 60 weeks · people with asthma
Subcutaneous omalizumab + steroid probably leads to lower hospitalisations 28 to 60 weeks compared with placebo + steroid (stable steroid) (moderate certainty).
1 finding from 1 review
- OR 0.16 [0.06, 0.42]4 studies · 1824 participantsModerate
Subcutaneous omalizumab + steroid vs placebo + steroid (stable steroid)
Adverse event—serious 16 to 60 weeks · people with asthma
Subcutaneous omalizumab + steroid probably leads to lower adverse event—serious 16 to 60 weeks compared with placebo + steroid (stable steroid) (moderate certainty).
1 finding from 1 review
- OR 0.72 [0.57, 0.91]15 studies · 5713 participantsModerate
Subcutaneous omalizumab + steroid vs placebo + steroid (steroid reduction)
Number of participants achieving complete inhaled steroid withdrawal 28 to 32 weeks · people with asthma
Subcutaneous omalizumab + steroid may leads to higher number of participants achieving complete inhaled steroid withdrawal… compared with placebo + steroid (steroid reduction) (low certainty).
1 finding from 1 review
- OR 2.5 [2, 3.13]4 studies · 1634 participantsLow
Subcutaneous omalizumab + steroid vs placebo + steroid (steroid reduction)
>50% reduction in inhaled steroid usage 28 to 32 weeks · people with asthma
Subcutaneous omalizumab + steroid probably leads to higher >50% reduction in inhaled steroid usage 28 to 32 weeks compared with placebo + steroid (steroid reduction) (moderate certainty).
1 finding from 1 review
- OR 2.5 [2.02, 3.1]4 studies · 1634 participantsModerate
Subcutaneous omalizumab + steroid vs placebo + steroid (steroid reduction)
Exacerbations needing hospitalisation · people with asthma
Subcutaneous omalizumab + steroid probably leads to lower exacerbations requiring hospitalisation 28 weeks compared with placebo + steroid (steroid reduction) (moderate certainty).
1 finding from 1 review
- OR 0.11 [0.03, 0.48]3 studies · 1405 participantsModerate
Aclidinium bromide vs placebo
Mortality (all‐cause) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in mortality (all‐cause) compared with placebo (low certainty).
1 finding from 1 review
- Aclidinium bromide for stable chronic obstructive pulmonary disease 2014 · Cochrane Headline outcomes onlyOR 0.92 [0.43, 1.94]9 studies · 5252 participantsLow